Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Roy, Archna
- Unitary Patent Protection, Unified Patent Court, Supplementary Protection Certificate and Brexit
Abstract Views :143 |
PDF Views:106
Authors
Affiliations
1 Intellectual Property Management Group, Lupin Limited, Lupin Research Park, Pune-411042, Maharashtra, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104, Karnataka, IN
1 Intellectual Property Management Group, Lupin Limited, Lupin Research Park, Pune-411042, Maharashtra, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104, Karnataka, IN
Source
Journal of Intellectual Property Rights, Vol 22, No 4 (2017), Pagination: 188-199Abstract
New development in terms of Unitary Patent Protection (UPP) system in Europe is anticipated by the end of the year 2017. This article reviews the advantage of UPP over European Patent system (EPS). In addition, the upcoming Unified Patent Court (UPC) system allows parties to litigate in a single forum which would be time saving and cost effective. In this article we have tried to briefly summarize the structure of UPC. There are certain areas like Supplementary Protection Certificate (SPCs) relating to pharmaceutical products which may be significantly impacted by UPP and UPC. We have tried to weigh the implications of the new system on SPC and also provide some possible solutions. Lastly, Britain’s exit from European Union, popularly referred to as Brexit, may pose some challenges to the UPC and UPP and might adversely affect the fundamental purpose of a single patent system in Europe.Keywords
UPC Agreement, SPC, Unified Patent Court, Brexit, Treaty on European Union.- Comparative Quantitative Analysis of Supplementary Protection Certificates (SPCs) in Europe
Abstract Views :161 |
PDF Views:91
Authors
Affiliations
1 Intellectual Property Management Group, Lupin Limited, Lupin Research Park, Pune-411042, Maharashtra, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104, Karnataka, IN
1 Intellectual Property Management Group, Lupin Limited, Lupin Research Park, Pune-411042, Maharashtra, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104, Karnataka, IN
Source
Journal of Intellectual Property Rights, Vol 22, No 1 (2017), Pagination: 16-22Abstract
This article is an attempt to quantify and compare number of SPCs granted, filed and invalidated in five important European Countries UK, France, Germany, Italy and Spain. The data is collected for those patents having expiry in between 1 January 1995 till 31 December 2025. The article further focuses on recent case laws evolved in Europe and its impact on SPC filings. The analysis reveals that patentees are inclined to file more SPCs on product patents as lesser percentage of SPCs for product patent got invalidated. There is a decline in SPCs for patents on combination product. In contrast patents on composition seems to drive highest number of SPC applications as patent holders are trying to extend the life cycle of the product through follow on products, improved articles. It will be interesting to see how the trend of SPC filing will change in future after rise of Unitary Patents.Keywords
Medeva, Actavis, SPC, Combination Patent, Sanofi, Lilly, CJEU, Carrier Protein, Markush Claims.- Comparative Analysis of Canadian ‘Certificate of Supplementary Protection’ with USA and Australian ‘Patent Term Extension’ and European ‘Supplementary Protection Certificate’
Abstract Views :167 |
PDF Views:136
Authors
Affiliations
1 Intellectual Property Management Group, Lupin Limited, Survey No. 46A/ 47A, Nande Village, Taluka Mulshi, Maharashtra - 412 115, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka - 576 104, IN
1 Intellectual Property Management Group, Lupin Limited, Survey No. 46A/ 47A, Nande Village, Taluka Mulshi, Maharashtra - 412 115, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka - 576 104, IN
Source
Journal of Intellectual Property Rights, Vol 23, No 4-5 (2018), Pagination: 167-173Abstract
As a result of Comprehensive Economic and Trade Agreement (CETA), for the first time, on 21 September 2017, Canada introduced Certificate of Supplementary Protection (CSP) regime. Before CETA was executed, Canada was the only country of G7 (Group of 7) countries not to legislate Patent Term Extension (PTE). This new regime is an important moment for the Canada’s intellectual property (IP) framework. On one hand, this regime provides an opportunity to innovators of pharmaceutical and veterinary products to recover investments made to obtain marketing authorizations for medicinal products, and on other hand, it impacts the timing of entry of generic products in the Canadian market. This article provides comprehensive information regarding the Canadian CSP and its comparative analysis with United States of America and Australian PTE and European Supplementary Protection Certificate (SPC).Keywords
Certificate of Supplementary Protection, Patent Term Extension, Supplementary Protection Certificate, Comprehensive Economic and Trade Agreement, TRIPS, Canadian Patent Act, Notice of compliance, Patent Term Adjustment, Regulatory Review Period, Investigational New Drug, Investigational Device Exemption, New Drug Application, Biologic License Application, Pre-Marketing Authorization, United States Food And Drug Administration, Therapeutic Goods Administration, Australian Register of Therapeutic Goods, Australian Patent Act, 1990, The Court of Justice of the European Union.References
- http://trade.ec.europa.eu/doclib/press/index.cfm?id=1723 (accessed on 7 January 2018).
- https://www.lexology.com/library/detail.aspx?g=66437b46-9961-455e-aacf-572f930796f2 (accessed on 7 January 2018).
- Canadian ‘Patent Act 1985’ amended on 21 September 2017.
- http://www.bcf.ca/en/current-affairs/829/ceta-and-phaimaceutical-patents-supplementary-protection-certificates-now-established-in-canada (accessed on 7 January 2018).
- Certificate of Supplementary Protection Regulations, Canada Gazette Part II, Extra Vol. 151, No. 1, 7 September, 2017.
- Section 115 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 118 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 124 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 123 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 116 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 104 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 105 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 106 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 122 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 114 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 126 of Canadian Patent Act, 1985 amended on 21 September 2017.
- Section 127 of Canadian Patent Act, 1985 amended on 21 September 2017.
- 35 U.S.C. § 154 and 35 U.S.C. § 156.
- https://www.accessdata.fda.gov/scripts/cder/ob/search_patent .cfm (07 January 2018).
- http://www.griffithhack.com/news/2017/swiss-type-claims-not-eligible-for-patent-term-extension-in-australia/ (accessed on 7 January 2018).
- Section 70 to 79 A of the Australian Patents Act, 1990.
- Alphapharm Pty Ltd v HLundbeckA/S [2014] FCA 1185.
- Commissioner o f Patents v Abb Vie Biotechnology Ltd [2017] FCAFC 129.
- Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009.
- Article 7 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009.
- Article 13 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009.
- http://www.khuranaandkhurana.com/2017/01/11/india-do-we-need-patent-term-extension-and-non-patent-exclusivities-for-pharmaceuticals/ (accessed on 11 January 2018).
- Merck Sharp & Dohme Corporation v Deutsches Patent, (Case C-125/10), 8 December 2011.
- Analysis of SPC Regulation Associated with Pharmaceutical Products in Europe
Abstract Views :197 |
PDF Views:132
Authors
Affiliations
1 Intellectual Property Management Group, Lupin Limited, Nande Village, Pune 412 115, Maharashtra, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576 104, Karnataka, IN
1 Intellectual Property Management Group, Lupin Limited, Nande Village, Pune 412 115, Maharashtra, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576 104, Karnataka, IN
Source
Journal of Intellectual Property Rights, Vol 23, No 6 (2018), Pagination: 233-242Abstract
The purpose of the study is to understand SPC regulations associated with pharmaceutical products. The study focuses on the case laws associated with SPC regulation and decisions handed down by national IP courts across Europe. The study also provides some guidelines for patent claim drafting with improved chances of getting and identifying avenues for challenging SPCs, as well as possible solutions and loopholes in SPC regulation. The guidelines for predictions of generic drug entry into market are discussed. The data collected and analyzed for individual European Country provides useful insight into pattern of SPC filing, grant and SPC invalidity. It is observed that there is a need to amend SPC regulation to provide better clarity to both innovators and generic drug industry.Keywords
Supplementary Protection Certificate, Patent Term Extension, Court of Justice for European Union, New Chemical Entity, European Free Trade Agreement, Ema, Generic Drug Industry.References
- Anon (2017), http://www.ipo.gov.uk/spctext.pdf (online) (accessed on 18 October 2017).
- Joshi O, Roy A & Janodia M, Supplementary Protection Certificate Provisions for pharmaceutical and biotechnological products in Europe: An era after Medeva and Georgetown, Journal o f Intellectual Property Rights, 19 (6) (2014) 377-386.
- Regulation (EC) No. 469/2009 of the European Parliament and of the Council of 6 May 2009.
- Council regulation (EEC) No 1768/92. 1992.
- Directive 2001/83/EC of the European Parliament and of the Council of November 6, 2001 on the Community code relating to medicinal products for human use, 2001.
- Eli Lilly v Human Genome Sciences, C-493/12. 2013.
- Georgetown University, University o f Rochester, Loyola University o f Chicago v Comptroller General o f Patents, Designs and Trade Marks, C-44/10. 2011
- Actavis v Boehringer Ingelheim Pharma, EWHC 2927. 2013.
- Joshi O, Roy A & Janodia M, Comparative quantitative analysis of Supplementary Protection Certificate (SPCs) in Europe, Journal o f Intellectual Property Rights, 22 (1) (2017) 16-22.
- Joshi O, Roy A, Janodia M. Unitary Patent Protection, Unified Patent Court, Supplementary Protection Certificate and Brexit Europe, Journal o f Intellectual Property Rights, 22 (4) (2017) 188-199.
- Regulation (EU) No 1257/2012 of the European Parliament and of the Council of 17 December 2012 implementing enhanced cooperation in the area of the creation of unitary patent protection, 2012.
- Council Regulation (EU) No 1260/2012 of 17 December 2012 implementing enhanced cooperation in the area of the creation of unitary patent protection with regard to the applicable translation arrangements, 2012.
- Kyle M, European Analysis of Supplementary Protection Certificates in Europe European Commission, MINES ParisTech; 2018.
- Jongh T de, Effects o f Supplementary Protection Mechanisms fo r Pharmaceutical Products, Technopolis Group; 2018.
- Case C:322/10,Medeva 2011, CJEU.
- Case C:422/10, Georgetown University, University o f Rochester, Loyola University o f Chicago v Comptroller General o f Patents, Designs and Trade Marks2011, CJEU 776.
- Case C:518/10, Yeda Research and Development Company Ltd 2011, CJEU.
- Case C:630/10, University o f Queensland v Comptroller General o f Patents, Designs and Trademarks 2011, CJEU.
- Case C:6/11. Daiichi Sankyo Company v Comptroller-General o f Patents2011, CJEU.
- Case C:443/12. Actavis v Sanofi 2013, CJEU.
- Langer I, Council Regulation (EC) No 207/2009 of 26 February 2009 on the Community trade mark (codified version) (Text with EEA relevance). Official Journal o f the European Communities, 2009, L(78) 1-42.
- Case C:210/13, GlaxoSmithKline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG v Comptroller-General o f Patents, Designs and Trade Marks2013, CJEU.
- Case C:442/11, Novartis AG v Actavis UK Limited 2012, CJEU.
- Case C:577/13, Actavis Group PTC EHF, Actavis UK L td v Boehringer Ingelheim Pharma GmbH & Co. KG, CJEU.
- SPC Regulation, Analysis of SPC Case Laws and Roadmap for Pharmaceutical Industry
Abstract Views :168 |
PDF Views:101
Authors
Affiliations
1 Intellectual Property Management Group, Lupin Limited, Nande Village, Pune, Maharashtra - 412 115, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka - 576 104, IN
1 Intellectual Property Management Group, Lupin Limited, Nande Village, Pune, Maharashtra - 412 115, IN
2 Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka - 576 104, IN
Source
Journal of Intellectual Property Rights, Vol 24, No 1&2 (2019), Pagination: 5-20Abstract
The purpose of the study is to understand Supplementary Protection Certificate (SPC) regulations associated with pharmaceutical products. In this study the case laws associated with SPC regulation and decisions handed down by national IP courts across Europe have been reviewed. On one hand, this study provided insights into innovator strategies in managing product lifecycles and on the other hand, it also helped in studying perspective of generic drug industry. A survey amongst IP experts about SPC regulation have also been carried out. It is observed that there is a need to amend the SPC regulation to provide better clarity to both innovators and generic drug industry.Keywords
SPC, Court of Justice for European Union, First Marketing Authorization, European Economic Community, Pediatric Extension, European Free Trade Association, New Chemical Entity, Pediatric Implementation Plan, Patent Term Extension, European Commission, Unitary Patent System, Patent Term Adjustment, Unified Patent Court System, One Product-Multiple Extension, One Patent-Multiple Extension.References
- UK Government. Supplementary Protection Certificates. London; 2018, https://www.gov.uk/guidance/supplementary: protection:certificates (accessed on 24 July 2017).
- Joshi O, Roy A & Janodia M, Supplementary protection certificate provisions for pharmaceutical and biotechnological products in Europe: An era after Medeva and Georgetown, Journal o f Intellectual Property Rights, 19 (6) (2014) 378-386 (accessed on 20 December 2015).
- Pottering H & Kohout J, Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products, Official Journal o f the European Union, 2009, L(152) 1-10.
- Maartins V, Council Regulation (EEC) No 1768/92 of 6 May 2009 concerning the supplementary protection certificate for medicinal products, Official Journal o f the European Communities, 1992, L(182) 1-15.
- Hansch K & Lowry M, Regulation (EC) No 1610/96 of the European Parliament and of the Council of 23 July 1996 concerning the creation of a supplementary protection certificate for plant protection products, Official Journal o f the European Communities, 1996, L(198) 30-35.
- Economic and Social Committee, Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, Official Journal o f the European Communities, 2001, OJ L(311) 67.
- Economic and Social Committee, Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products, Official Journal o f the European Communities, 2001, OJ L(311) 1.
- Fontelles J & Pekkarinen M, Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for pediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, Official Journal o f the European Communities, 2006, L(378) 1-19.
- Schulz M & Mavroyiannis A, Regulation (EU) No 1257/2012 of the European Parliament and of the Council of 17 December 2012 implementing enhanced cooperation in the area of the creation of unitary patent protection, Official Journal o f the European Communities, 2012 L(361) 1-8.
- Aletreris S, Council Regulation (EU) No 1260/2012 of 17 December 2012 implementing enhanced cooperation in the area of the creation of unitary patent protection with regard to the applicable translation arrangements, Official Journal o f the European Communities, 2012 L(361) 89:92.
- Langer I, Council Regulation (EC) No 207/2009 of 26 February 2009 on the Community trade mark (codified version) (Text with EEA relevance), Official Journal o f the European Communities, 2009 L(78) 1-42.
- European Patent Office, The European Patent Convention, https://www.epo.org/law:practice/legal:texts/html/epc/2016/ e/ar121.html (accessed on 25 July 2018).
- Case C: 431/04, Massachusetts Institute o f Technology 2006, CJEU.
- Case C: 130/11, Neurim Pharmaceuticals Ltd v ComptrollerGeneral o f Patents, 2011, CJEU.
- Trojborg J, Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, 1993, L(169) 1:43.
- O’Malley D, Council Directive of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices (90/385/EEC), Official Journal o f the European Communities, 1990 L(189) 17-36.
- Case C: 493/12, Eli Lilly v Human Genome Sciences, 2013, CJEU 45/24.
- Case C: 422/10, Georgetown University, University o f Rochester, Loyola University o f Chicago v Comptroller General o f Patents, Designs and Trade Marks, 2011, CJEU 776.
- Case 2927 (Pat), Actavis v Boehringer Ingelheim Pharma 2013, EWHC.
- Case C: 392/97, Farmitalia, 2000, CJEU.
- Case SPC/GB93/017, Takeda 1993, (unreported oral decision).
- Case 4, Centocor Inc's SPC Application, 1996, RPC 118.
- ase 2, Takeda Chemical Industries Ltd's Applications 2004, RPC 20.
- Case 646 (Pat), Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd 2009, EWCA.
- Case 1902 (Pat), Gilead Sciences, Inc. 2008, EWHC.
- Case 1916 (Pat), Astellas Pharma Inc v Comptroller-General o f Patents 2009, EWHC.
- Case 2897 (Pat), Daiichi Sankyo Company Limited v Comptroller General o f Patents 2010. EWHC.
- Case C: 6/11, Daiichi Sankyo Company v ComptrollerGeneral o f Patents 2011, CJEU.
- Case C: 322/10, Medeva 2011, CJEU.
- Case C: 630/10, University o f Queensland, CSL Ltd. 2011, CJEU.
- Case C: 518/10, Yeda Research and Development Company Ltd 2011, CJEU.
- Case C: 577/13, Actavis Group PTC EHF, Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. KG. CJEU.
- Case BL O/066/10, Imclone Systems Inc. Ltd & Aventis Holdings Inc 2010.
- Case BL O552/14, Icahn School o f Medicine at Mount Sinai 2014.
- Case 987, Sandoz Ltd & Anor v G.D. Searle & Anor 2017, EWHC.
- Case 181, Novartis Pharmaceuticals UK Limited and Medimmune Limited/Medical Research Council 2012, EWHC.
- Case 2545, Actavis Group PTC EHF / Actavis UK Limited and Sanofi and Sanofi Pharma Bristol Myers Squibb SNC 2012, EWHC.
- Joshi O, Roy A & Janodia M, Supplementary Protection Certificate (SPC) for combination products: “Protection of incremental inventions” in pharmaceutical field after Court of Justice of European Union (CJEU) ruling in Actavis case, NTUTJIPLM, 4 (2) (2015) 108-112.
- Case C: 443/12, Actavis v Sanofi 2013, CJEU.
- Case 13, Teva UK & Ors v Gilead 2017, EWHC.
- Case C: 631:13, Forsgren v Osterreichisches Patentamt 2015. CJEU.
- Case 3, British Technology Group Ltd's SPC Application 1997, RPC 50.
- Case BL O/117/16, Merck Sharp & Dohme Corporation, 2016.
- Case 24, Chiron Corporation and Novo Nordisk A/S 2005, RPC 587.
- Case C: 482/07, AHP Manufacturing BV v Bureau voor de Industriele Eigendom 2009, CJEU.
- Case C: 484/12, Hague in Georgetown University and Octrooicentrum Nederland 2013, CJEU.
- Case 539, Teva UK Limited & Ors v Merck Sharp & Dohme Corporation 2017, EWHC.
- Case BL O/222/04, Yissum Research & Development Company o f the Hebrew University o f Jerusalem 2004.
- Case BL O/384/09, Neurim Pharmaceuticals Ltd's SPC Application 2009.
- Case 14, Abraxis Bioscience LLC v Comptroller General o f Patents 2017, EWHC.
- Case C: 442/11, Novartis AG v Actavis UK Limited 2012, CJEU.
- Case BL O/098/15, Otsuka Pharmaceuticals Company Limited's Application 2015.
- Case BL O/035/09, Merck 2009.
- Case 966, EI du Pont de Nemours & Co v UK Intellectual Property Office 2009, EWCA.
- Case C: 630/10, University o f Queensland v Comptroller General o f Patents, Designs and Trademarks 2011, CJEU.
- Case C: 210/13, GlaxoSmithKline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG, v Comptroller-General o f Patents, Designs and Trade Marks2013, CJEU.
- European Patent Office, The European Patent Convention. Available from: https://www.epo.org/law:practice/legal: texts/html/epc/2016/e/ar121.html (accessed on 25 July 2018).
- Frohlinger M, The Unitary Patent: Opportunity or Challenge? Ljubljana (Presentation), 2016.
- Joshi O, Roy A & Janodia M, Unitary Patent Protection, Unified Patent Court, Supplementary Protection Certificate and Brexit, Journal o f Intellectual Property Rights, 22 (4) (2017) 188-199..
- Joshi O, Roy A & Janodia M, PTE provisions relating to pharmaceutical products in Australia in comparison with European SPC and USA PTE, Journal o f Intellectual Property Rights, 20 (3) (2015) 147-154.
- Malwina M, 25 years o f SPC protection for medicinal products in Europe: Insights and challenges, European Commission, 2017.
- Thyra de J, Effects o f supplementary protection mechanisms for pharmaceutical products, Technopolis Group, 2018.
- Raphael De C, Assessing the economic impacts o f changing exemption provisions during patent and SPC protection in Europe, Charles River Associates, 2016.
- Margaret K, Economic Analysis o f Supplementary Protection Certificates in Europe, MINES ParisTech, 2017.
- Timo M, Study on the economic impact o f supplementary protection certificates, pharmaceutical incentives and rewards in Europe, Copenhagen Economics, 2018.
- Hilty R, Study on the legal aspects o f Supplementary Protection Certificate in the EU, Max Planck Institute for Innovation and Competition, 2018.